Liraglutide reduced infarct size in the brain of diabetic and non-diabetic rats but decreased neurologic deficits only in non-diabetic rats, suggesting that the GLP-1 RAs effects on cognitive function are not associated with diabetes and glycemia normalization. Here, GLP1R is linked to diabetes mellitus.